Recent performance context for West Pharmaceutical Services

West Pharmaceutical Services (WST) has drawn attention after a recent share move, with the stock closing at US$328.82 and showing varied returns over the past month, past 3 months, and year.

The recent 4.6% 7 day share price return and 36.8% 90 day share price return suggest momentum has picked up again, while the 48.7% 1 year total shareholder return contrasts with weaker 3 and 5 year outcomes.

If this kind of rebound has you thinking about what else might be setting up for future gains, it could be worth scanning 20 top founder-led companies

With WST trading at US$328.82 and sitting roughly 9% below a US$358.79 analyst price target, along with an intrinsic value estimate that sits far above today’s price, investors may wish to consider whether there is a buying opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 7% Undervalued

The most followed narrative pegs West Pharmaceutical Services' fair value at about $352 per share, a step above the recent $328.82 close, and ties that gap to how its injectable platforms and higher value mix could shape earnings.

The continued growth in GLP-1s, which made up about 7% of total revenues in the first quarter, and the company's ability to capitalize on significant opportunities in this market could drive revenue and earnings growth. The anticipated high single-digit growth rate for Biologics HVP components in the second half of 2025, despite initial destocking challenges, shows potential for revenue acceleration and earnings improvement.

Want to see what sits behind that premium valuation gap? This narrative leans on a specific earnings path, richer margins, and a future P/E that needs real conviction.

Result: Fair Value of $352 (UNDERVALUED)

However, this narrative can be shaken if demand shifts away from high value components, or if tariffs and pricing pressure squeeze margins more than analysts expect.

Another View on Valuation

That fair value of about $352 leans on analyst forecasts, but the market is telling a different story through the current P/E of 42.8x. That is higher than the fair ratio of 21.3x, the US Life Sciences average of 37.8x, and the global industry at 33.9x, which points to potential valuation risk if sentiment cools.

For a closer look at how this richer multiple compares, including where the fair ratio suggests the market could drift over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mixed sentiment has you weighing both the upside story and valuation risk, it makes sense to review the numbers yourself and move quickly while opinions are split. To see what the market is currently optimistic about, start with the 2 key rewards.

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that match your style, so put the Simply Wall St Screener to work for you.

• Spot potential value opportunities early by scanning 44 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
• Prioritize resilience by focusing on 71 resilient stocks with low risk scores that score well on financial strength and business stability.
• Get ahead of the crowd by reviewing the screener containing 20 high quality undiscovered gems that may not yet be widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.